Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors potentially useful for the treatment of cancer have been described in a recent Scorpion Therapeutics Inc. patent.
Researchers from Shenyang Pharmaceutical University and affiliated organizations have reported the identification of a selective cyclin-dependent kinase 9 (CDK9) inhibitor, CLZX-205, being developed for the treatment of colorectal cancer.
Accession Therapeutics Ltd. has raised £25 million (US$31.3 million) to fund it through the generation of the first clinical data for its lead product, TROCEPT-01 (ATTR-01), and completion of IND-enabling studies for a second program. The internal early-stage pipeline will also be progressed.
Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.
Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK1/cyclin B and/or CDK2/cyclin E1 and/or CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors, reported to be useful for the treatment of cancer.
Dana-Farber Cancer Institute Inc. has disclosed covalent inhibitors of serine/threonine-protein kinase A-Raf (ARAF) reported to be useful for the treatment of carcinoma and melanoma.
Researchers from the Chinese Academy of Sciences and affiliated organizations discovered a new ubiquitin-specific protease 7 (USP7) inhibitor, YCH-2823, being developed as a potential anticancer agent.